Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
IntroductionFirst-line treatment with tislelizumab plus chemotherapy has shown clinical benefits for patients with advanced or metastatic esophageal squamous cell carcinoma (OSCC) in China, while its economic burden is unknown. This study aimed to evaluate the cost-effectiveness of tislelizumab plus...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2024-05-01
|
| coleção: | Frontiers in Pharmacology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1225076/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|